In a recent paper published by Chen et al., PI3K/mTOR dual inhibitor BEZ235 displayed higher therapeutic efficiency than everolimus or the MEK inhibitor AZD6244 in paclitaxel-resistant GC cells [18]. This evidence concerns the gene PIK3CA and gastric cancer.